Biocon growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+10.9%+3.4%+32.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+9.1%−4.0%+31.3%
+1.3%−14.5%+23.7%
−74.2%+10.1%+101.8%
−66.7%−1.1%+120.4%
+8.3%+4.9%+7.7%
+32.1%+9.6%+12.4%
−50.9%+37.5%+59.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BIOCON₹351.90

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹57,043 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+32.1+3.4+10.9—
EBITDA Growth—+31.3-4.0+9.1—
EBIT Growth—+23.7-14.5+1.3—
Net Income Growth—+101.8+10.1-74.2—
EPS Growth—+120.4-1.1-66.7—
Total Assets Growth—+7.7+4.9+8.3—
Total Equity Growth—+12.4+9.6+32.1—
Cash from Operations Growth—+59.5+37.5-50.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.